30.technologyCrawled Nov 13, 2026
The clinical trial RESP30X-EBA is active and recruiting participants at the TASK Clinical Research Centre in South Africa.
RESP301 to combat antibiotic resistant/refractory infection in people with cystic fibrosis
Nitric oxide has long been recognized as a potent antimicrobial molecule produced by the human immune system. However, therapeutic use of nitric oxide has historically been limited to inhalation of nitric oxide as a gas, which has inherent weaknesses:
Nitric oxide is a volatile, short-lived molecule continuously produced by the body and is critical to regulating blood flow, driving the immune response, accelerating healing, and fighting infections.
Thirty Technology joins the fight against antibiotic resistant infection.
30 Technology has been actively engaged in expanding its clinical team to drive its lead respiratory assets through multiple ongoing early phase clinical trials.
30 Technology received full regulatory approval to begin a Phase 2 trial for pulmonary tuberculosis in adults.
Check back again to view any new positions which become available.
30 Technology’s nitric oxide platform delivers sustained, high-dose nitric oxide in inhaled, topical, and powder forms for clinical use, initially targeting respiratory disease, oral health, dermatology, rare diseases, and animal health.
30 Technology partners with healthcare experts to advance research and develop new applications.
1 Red Place London W1K 6PL United Kingdom +44 (0) 1235 431 201
Favourable safety and tolerability profile, high treatment compliance and encouraging efficacy signals sustained through one-month follow-up support continued development of RESP303 in chronic respiratory infections.
30 Technology collects, stores, and processes personal information about staff, suppliers, customers, and others, ensuring compliance with data handling laws.
30 Technology explains how it collects, uses, and protects personal information from users.
